Europe Precision Medicine Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

Precision medicine in Europe encompasses diagnostics, targeted therapies, companion diagnostics, and digital health platforms tailored to individual patient profiles. The market was valued at approximately $27.5 billion in 2025 and is forecast to experience strong compound growth through the early 2030s, with some projections pointing toward a market size approaching $119 billion by 2034. Growth is supported by expanding healthcare infrastructure investments and the integration of genomics into routine clinical practice across the European Union.

• •Market valued at approximately $27.5 billion in 2025 with a projected CAGR of around 14.3%
• •Some industry analysis projects the market could reach approximately $118.79 billion by 2034
• •Market segments typically analyzed by application, component type, and individual country

The declining cost of whole-genome sequencing and next-generation sequencing technologies has made genomic profiling increasingly accessible across European healthcare systems. Regulatory bodies such as the European Medicines Agency have established frameworks to support companion diagnostics and personalized therapeutics, creating a more favorable environment for market expansion.

• •Falling costs of genomic sequencing and NGS technologies expanding clinical adoption
• •Supportive regulatory frameworks from the EMA enabling companion diagnostics approvals
• •Growing cancer prevalence driving demand for targeted therapies and biomarker-driven diagnostics

The market is commonly segmented by application area, component type, and geographic country, with country-level analysis reflecting varying rates of healthcare digitization and genomic infrastructure investment across Europe. Western European nations, particularly Germany, the United Kingdom, and France, have historically accounted for the largest share of precision medicine spending, while Eastern European markets are showing accelerating growth as healthcare systems modernize.

• •Segmented by application, component, and individual country for granular analysis
• •Western Europe leads in adoption, driven by Germany, UK, and France
• •Eastern European markets emerging as healthcare digitization and genomic infrastructure expand

What are the recent trends and outlook?

Artificial intelligence and machine learning are increasingly being integrated into precision medicine workflows for biomarker discovery, patient stratification, and treatment optimization across European research and clinical settings. Digital health platforms and telemedicine are extending the reach of personalized care, while multi-omics approaches combining genomics, proteomics, and metabolomics are becoming more prominent in drug development pipelines. The market is expected to sustain its strong growth trajectory through 2034, supported by continued policy support, cross-border research collaboration, and expanding reimbursement frameworks for personalized treatments.

• •AI and machine learning accelerating biomarker discovery and patient stratification efforts
• •Multi-omics integration becoming central to pharmaceutical R&D pipelines
• •Continued market expansion expected through 2034 driven by policy support and reimbursement framework evolution